The notices it replaced
- Reissues: RFA-OD-20-005 Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
- 2 steps back: RFA-OD-19-016 Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
Replaced by RFA-OD-27-004.
Who won it before
47 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $94,550,301 in first-year total cost, median $1,959,062.
Most frequent study sections
- Special Emphasis Panel[ZRG1 VH-A (90)]17
- Special Emphasis Panel[ZRG1 IVBH-B (57)]7
- Special Emphasis Panel[ZRG1 BST-J (50)]6
- Special Emphasis Panel[ZRG1 BST-L (51)]6
- Special Emphasis Panel[ZRG1 BST-W (55)]6
Most frequent institutions
- UNIVERSITY OF COLORADO DENVER10
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI3
- INDIANA UNIVERSITY INDIANAPOLIS2
- TEXAS A&M AGRILIFE RESEARCH2
- UNIVERSITY OF CALIFORNIA, SAN DIEGO2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Modifiers of Down Syndrome Co-occurring Phenotypes1R01HD118475-01 | ROPER, RANDALL J | INDIANA UNIVERSITY INDIANAPOLIS, IN | $1,303,054 | ZRG1 |
| 2025 | Transposable Element Mobilization and Disrupted Translational Machinery in Down Syndrome1RF1NS142871-01 | KALISH, BRIAN | BOSTON CHILDREN'S HOSPITAL, MA | $1,274,904 | ZRG1 |
| 2025 | A humanized monoclonal FSH antibody for Alzheimer's Disease and co-occurring health conditions in Down Syndrome1R01AG093773-01 | GOOSENS, KI ANNZAIDI, MONE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,257,163 | ZRG1 |
| 2025 | Allelic Expression Imbalance in Trisomy 211RF1NS142814-01 | THAYER, MATHEW J | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $780,000 | ZRG1 |
| 2024 | The role of immune deregulation and NGF dysmetabolism in the development of Alzheimer disease in individuals with Down syndrome1R01AG087280-01 | BUSCIGLIO, JORGE ACUELLO, A CLAUDIOFORTEA, JUANWISNIEWSKI, THOMAS M | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $1,105,775 | ZRG1 |
| 2024 | Multidimensional investigation of auditory dysfunction in Down syndrome1R01DC021819-01 | ESPINOSA, JOAQUIN M.MERCHANT, GABRIELLE RYANSTEYGER, PETER STEPHEN | UNIVERSITY OF COLORADO DENVER, CO | $942,771 | ZRG1 |
| 2024 | Large-scale Genetic Investigation and Drug Discovery to Counteract Down Syndrome Neural Deficits1R01HD115159-01 | THYME, SUMMER B | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $826,661 | ZRG1 |
| 2024 | Preventing Fatal Infections in Children with Down Syndrome During Treatment for Acute Lymphoblastic Leukemia1R01CA290539-01 | GUIDOS, CYNTHIA J.RABIN, KAREN RRYEOM, SANDRA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $548,211 | ZRG1 |
| 2024 | Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome1R01NS137222-01 | DIERSSEN, MARAVALERO GARCIA, MANUELYE, BING | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $458,523 | ZRG1 |
| 2024 | Intrinsic and Extrinsic Factors Contributing to Trisomy 21 Preleukemia1R01CA290681-01 | WAGENBLAST, ELVIN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $426,919 | ZRG1 |
| 2024 | Enhancing treatments for myeloid leukemia associated with Down syndrome1R01CA290480-01 | GE, YUBINTAUB, JEFFREY WARREN | WAYNE STATE UNIVERSITY, MI | $306,623 | ZRG1 |
| 2023 | A heterochronic model for birth defects in Down Syndrome1R01HD111938-01 | MOSKOWITZ, IVAN PAUL | UNIVERSITY OF CHICAGO, IL | $5,035,031 | ZRG1 |
| 2023 | Defining the Role of Enteric Nervous System Dysfunction in Gastrointestinal Motor and Sensory Abnormalities in Down Syndrome1RF1NS128738-01A1 | BELKIND-GERSON, JAIMEFRANK, DANIEL NSULLIVAN, KELLY D. | UNIVERSITY OF COLORADO DENVER, CO | $2,837,478 | ZRG1 |
| 2023 | Investigating and targeting apolipoprotein E4 in Down syndrome-associated Alzheimer's disease1RF1AG078965-01A1 | JOHNSON, NOAH RAY | UNIVERSITY OF COLORADO DENVER, CO | $2,282,487 | ZRG1 |
| 2023 | A mosaic Down syndrome model system comparing isogenic trisomic/disomic cells to unmask trisomy-21 related genomic, epigenomic, and senescence changes acquired across the lifespan1R01HD111943-01 | JACKSON-COOK, COLLEEN K | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $2,217,370 | ZRG1 |
| 2023 | Investigating epigenetic mechanisms in Down syndrome using human cellular models1R01HD111876-01 | BARRETT, LINDY ELISE | BROAD INSTITUTE, INC., MA | $2,034,753 | ZRG1 |
| 2023 | SIM2 Regulation of Mitochondrial Dysfunction in Down Syndrome1R01HD111848-01 | PORTER, WESTON W | TEXAS A&M AGRILIFE RESEARCH, TX | $1,960,246 | ZRG1 |
| 2023 | A Physiologically Integrated Approach to Studying Mechanisms of Speech Production and Swallow Function in Down Syndrome1R01DC020622-01A1 | WILKINSON, KRISTA M | PENNSYLVANIA STATE UNIVERSITY, THE, PA | $1,959,062 | ZRG1 |
| 2023 | Determining cell-specific mechanisms that drive aberrant bone regeneration in Down syndrome1RF1AG081812-01 | DAWSON, LINDSAY A | TEXAS A&M AGRILIFE RESEARCH, TX | $1,633,451 | ZRG1 |
| 2023 | Molecular mechanisms of oral deficiencies in Down syndrome1R01DE032846-01 | LACRUZ, RODRIGO S. | NEW YORK UNIVERSITY, NY | $1,513,264 | ZRG1 |
| 2023 | Investigating the Mechanism of Optic Nerve disorders associated with Down Syndrome1R01EY033141-01A1 | MUKHERJEE, KONARK | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $1 | ZRG1 |
| 2022 | Neurovascular unit dysfunction in Down syndrome revealed by TBI1RF1NS128739-01 · under RFA-OD-20-005 | HUANG, MINGXIAPOTTER, HUNTINGTONSULLIVAN, KELLY D. | UNIVERSITY OF COLORADO DENVER, CO | $2,601,812 | ZRG1 |
| 2022 | Why do Down Syndrome patients have high risk of Hirschsprung disease?1R01DK135089-01 · under RFA-OD-20-005 | CHAKRAVARTI, ARAVINDACHATTERJEE, SUMANTRADAVOLI, TERESA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $2,486,641 | ZRG1 |
| 2022 | Novel computational strategies to deconvolute co-occurring conditions in Down syndrome1R01HD109765-01 · under RFA-OD-20-005 | COSTELLO, JAMES CHRISTOPHERGREENE, CASEY S | UNIVERSITY OF COLORADO DENVER, CO | $2,353,137 | ZRG1 |
| 2022 | The role of APP in neurogenesis and AD in Down syndrome1RF1AG079002-01 · under RFA-OD-20-005 | LAZAROV, ORLY | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $2,005,131 | ZRG1 |
| 2022 | Restoration of proteostasis to address co-occurring conditions in Down Syndrome1RF1AG078969-01 · under RFA-OD-20-005 | NAIDOO, NIRMALA NIRINJINI | UNIVERSITY OF PENNSYLVANIA, PA | $1,856,328 | ZRG1 |
| 2022 | Down Syndrome: a potential treatment XISTs1R01HD109794-01 · under RFA-OD-20-005 | SHEEN, VOLNEY L | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,693,316 | ZRG1 |
| 2022 | Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficits1R01HD109750-01 · under RFA-OD-20-005 | YU, EUGENE | ROSWELL PARK CANCER INSTITUTE CORP, NY | $475,839 | ZRG1 |
| 2021 | Human cortical development and neural plasticity altered by trisomy 211R01HD106197-01 · under RFA-OD-20-005 | BHATTACHARYYA, ANITAZHANG, SU-CHUN | UNIVERSITY OF WISCONSIN-MADISON, WI | $7,005,920 | ZRG1 |
| 2021 | Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome1RF1AG073979-01 · under RFA-OD-20-005 | RAFII, MICHAEL SRISSMAN, ROBERT | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $2,328,791 | ZRG1 |
| 2021 | Emulating Immune Dysregulation by Trisomy 21 in a Multi-Organ-on-a-Chip System1R01HL159494-01 · under RFA-OD-20-005 | HAJIPOURAN BENAM, KAMBEZ | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $2,101,852 | ZRG1 |
| 2021 | A Human iPSC-Based Chimeric Mouse Model of Alzheimers Disease in Down Syndrome1R01AG073779-01 · under RFA-OD-20-005 | JIANG, PENG | RUTGERS, THE STATE UNIV OF N.J., NJ | $2,008,397 | ZRG1 |
| 2021 | Defining the Role of DNA Rereplication of Chromosome 21 in the Development and Pathophysiology of Down Syndrome1R01AI155918-01 · under RFA-OD-20-005 | BLACK, JOSHUA CRANSTONSULLIVAN, KELLY D. | UNIVERSITY OF COLORADO DENVER, CO | $1,918,500 | ZRG1 |
| 2021 | Molecular mechanism of dysregulated airway antiviral responses in children with Trisomy 211R01HL159595-01 · under RFA-OD-20-005 | JAISWAL, JYOTI KNINO, GUSTAVO | CHILDREN'S RESEARCH INSTITUTE, DC | $1,643,687 | ZRG1 |
| 2021 | New Down syndrome brain organization revealed by single-cell genomics1R56AG073965-01 · under RFA-OD-20-005 | CHUN, JEROLD | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $1,395,349 | ZRG1 |
| 2021 | Targeting protein synthesis dysregulation in Down syndrome-associated cognitive impairment with aging1R01AG073823-01 · under RFA-OD-20-005 | MA, TAO | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $1,142,664 | ZRG1 |
| 2020 | Multiplexed Single Nucleus RNA and ATAC-seq Sequencing and Cortical Organoids: Transformative Insights into Down Syndrome1R01AG070154-01 · under RFA-OD-20-005 | MOBLEY, WILLIAM CROSENFELD, MICHAEL G | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $5,047,008 | ZRG1 |
| 2020 | Characterizing Innate Immune Dysregulation in Tonsils of Individuals with Down Syndrome1R01HL155691-01 · under RFA-OD-20-005 | VERNERIS, MICHAEL R. | UNIVERSITY OF COLORADO DENVER, CO | $3,038,439 | ZRG1 |
| 2020 | Down Syndrome as a systemic autophagy deficiency disorder1R01HD103828-01 · under RFA-OD-20-005 | DEGREGORI, JAMES VTHORBURN, ANDREW M | UNIVERSITY OF COLORADO DENVER, CO | $2,594,673 | ZRG1 |
| 2020 | Strategies for treatment of Down syndrome: Identifying age- and sex-specific developmental windows using inducible genetic reduction of Dyrk1a1R01AR078663-01 · under RFA-OD-20-005 | GOODLETT, CHARLES R.ROPER, RANDALL J | INDIANA UNIVERSITY INDIANAPOLIS, IN | $1,919,804 | ZRG1 |
| 2020 | Noradrenergic dysfunction in Down Syndrome1RF1AG070153-01 · under RFA-OD-20-005 | LEDREUX, AURÉLIE | UNIVERSITY OF DENVER (COLORADO SEMINARY), CO | $264,005 | ZRG1 |
| 2019 | Molecular Causes of Down Syndrome Associated Congenital Heart Disease and Other Phenotypes1R01HL151257-01 · under RFA-OD-19-016 | SEIDMAN, JONATHAN G | HARVARD MEDICAL SCHOOL, MA | $3,724,305 | ZRG1 |
| 2019 | Understanding the complexity of gene dosage imbalance in Down syndrome1R01HL151260-01 · under RFA-OD-19-016 | CHOU, STELLA T | CHILDREN'S HOSP OF PHILADELPHIA, PA | $3,352,210 | ZRG1 |
| 2019 | Type I Interferon Dysregulation in Down Syndrome1R01AI150300-01 · under RFA-OD-19-016 | BOGUNOVIC, DUSAN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $3,207,900 | ZRG1 |
| 2019 | Understanding Down Syndrome as an Interferonopathy1R01AI150305-01 · under RFA-OD-19-016 | ESPINOSA, JOAQUIN M. | UNIVERSITY OF COLORADO DENVER, CO | $2,830,725 | ZRG1 |
| 2019 | Trisomy 21 and RNA polymerase II function1R01HD100935-01 · under RFA-OD-19-016 | BENTLEY, DAVID L | UNIVERSITY OF COLORADO DENVER, CO | $2,828,221 | ZRG1 |
| 2019 | Elevated mitochondrial fusion and function in Down syndrome1R01HD101006-01 · under RFA-OD-19-016 | ROTHERMEL, BEVERLY A | UT SOUTHWESTERN MEDICAL CENTER, TX | $2,021,900 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.